Bibliometric analysis of biologic treatments for chronic rhinosinusitis

BackgroundChronic rhinosinusitis (CRS) significantly impacts patients’ quality of life. The use of biologic therapies in CRS management has gained traction in clinical practice. However, no bibliometric analysis has been conducted in this area thus far. This study aims to provide a comprehensive ove...

Full description

Saved in:
Bibliographic Details
Main Authors: Yue Huang, Yulan Chen, Qihong Li, Wen Sui, Zhuo Pan, Hao Yang, Zeyi Lv, Xi Chen, Man Yin, Yu Li, Xinrong Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1623940/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849393111222976512
author Yue Huang
Yulan Chen
Qihong Li
Wen Sui
Zhuo Pan
Hao Yang
Zeyi Lv
Xi Chen
Man Yin
Yu Li
Xinrong Li
author_facet Yue Huang
Yulan Chen
Qihong Li
Wen Sui
Zhuo Pan
Hao Yang
Zeyi Lv
Xi Chen
Man Yin
Yu Li
Xinrong Li
author_sort Yue Huang
collection DOAJ
description BackgroundChronic rhinosinusitis (CRS) significantly impacts patients’ quality of life. The use of biologic therapies in CRS management has gained traction in clinical practice. However, no bibliometric analysis has been conducted in this area thus far. This study aims to provide a comprehensive overview of the knowledge framework and research trends regarding biologic treatments for CRS.MethodsA bibliometric analysis was performed on 888 publications related to biologic treatments for CRS, published between 2011 and 2024. Literature was retrieved from the Web of Science (WoS), and data visualization and trend analysis were conducted using VOSviewer, CiteSpace, and Bibliometrix software tools.ResultsResearch on biologic therapies for CRS peaked in the past 6 years. Key contributors include Claus Bachert, the United States, and the University of Ghent. The most cited article is “Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trials.” The five most explosive keywords are: expression (5.03), placebo-controlled trial (3.68), anti-IgE (3.35), anti-IgE antibody (3.22), and phenotypes (4.55). Current research on biologic treatments for CRS predominantly focuses on clinical applications.ConclusionThis study offers a bibliometric visualization of the literature on biologic treatments for CRS, highlighting key developments and emerging research trends in the field. It provides valuable references for scholars and outlines future research directions to further advance the field.
format Article
id doaj-art-e091844dcfcc4793858bb6ec786c58c4
institution Kabale University
issn 2296-858X
language English
publishDate 2025-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Medicine
spelling doaj-art-e091844dcfcc4793858bb6ec786c58c42025-08-20T03:40:33ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-08-011210.3389/fmed.2025.16239401623940Bibliometric analysis of biologic treatments for chronic rhinosinusitisYue HuangYulan ChenQihong LiWen SuiZhuo PanHao YangZeyi LvXi ChenMan YinYu LiXinrong LiBackgroundChronic rhinosinusitis (CRS) significantly impacts patients’ quality of life. The use of biologic therapies in CRS management has gained traction in clinical practice. However, no bibliometric analysis has been conducted in this area thus far. This study aims to provide a comprehensive overview of the knowledge framework and research trends regarding biologic treatments for CRS.MethodsA bibliometric analysis was performed on 888 publications related to biologic treatments for CRS, published between 2011 and 2024. Literature was retrieved from the Web of Science (WoS), and data visualization and trend analysis were conducted using VOSviewer, CiteSpace, and Bibliometrix software tools.ResultsResearch on biologic therapies for CRS peaked in the past 6 years. Key contributors include Claus Bachert, the United States, and the University of Ghent. The most cited article is “Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trials.” The five most explosive keywords are: expression (5.03), placebo-controlled trial (3.68), anti-IgE (3.35), anti-IgE antibody (3.22), and phenotypes (4.55). Current research on biologic treatments for CRS predominantly focuses on clinical applications.ConclusionThis study offers a bibliometric visualization of the literature on biologic treatments for CRS, highlighting key developments and emerging research trends in the field. It provides valuable references for scholars and outlines future research directions to further advance the field.https://www.frontiersin.org/articles/10.3389/fmed.2025.1623940/fullchronic rhinosinusitisbiologic treatmentsbibliometricvisualized analysisemerging trends
spellingShingle Yue Huang
Yulan Chen
Qihong Li
Wen Sui
Zhuo Pan
Hao Yang
Zeyi Lv
Xi Chen
Man Yin
Yu Li
Xinrong Li
Bibliometric analysis of biologic treatments for chronic rhinosinusitis
Frontiers in Medicine
chronic rhinosinusitis
biologic treatments
bibliometric
visualized analysis
emerging trends
title Bibliometric analysis of biologic treatments for chronic rhinosinusitis
title_full Bibliometric analysis of biologic treatments for chronic rhinosinusitis
title_fullStr Bibliometric analysis of biologic treatments for chronic rhinosinusitis
title_full_unstemmed Bibliometric analysis of biologic treatments for chronic rhinosinusitis
title_short Bibliometric analysis of biologic treatments for chronic rhinosinusitis
title_sort bibliometric analysis of biologic treatments for chronic rhinosinusitis
topic chronic rhinosinusitis
biologic treatments
bibliometric
visualized analysis
emerging trends
url https://www.frontiersin.org/articles/10.3389/fmed.2025.1623940/full
work_keys_str_mv AT yuehuang bibliometricanalysisofbiologictreatmentsforchronicrhinosinusitis
AT yulanchen bibliometricanalysisofbiologictreatmentsforchronicrhinosinusitis
AT qihongli bibliometricanalysisofbiologictreatmentsforchronicrhinosinusitis
AT wensui bibliometricanalysisofbiologictreatmentsforchronicrhinosinusitis
AT zhuopan bibliometricanalysisofbiologictreatmentsforchronicrhinosinusitis
AT haoyang bibliometricanalysisofbiologictreatmentsforchronicrhinosinusitis
AT zeyilv bibliometricanalysisofbiologictreatmentsforchronicrhinosinusitis
AT xichen bibliometricanalysisofbiologictreatmentsforchronicrhinosinusitis
AT manyin bibliometricanalysisofbiologictreatmentsforchronicrhinosinusitis
AT yuli bibliometricanalysisofbiologictreatmentsforchronicrhinosinusitis
AT xinrongli bibliometricanalysisofbiologictreatmentsforchronicrhinosinusitis